Early clinical response in patients with migraine in treatment with anti-CGRP monoclonal antibodies: a possible "loading dose" effect?

被引：0
|
作者：
Ceccardi, Giulia
di Cola, Francesca Schiano
Bolchini, Marco
Di Pasquale, Michele
Rao, Renata
Padovani, Alessandro
机构：
[1] ASST Spedali Civili, Neurol Unit, Brescia, Italy
[2] ASST Spedali Civili, Headache Ctr, Dipartimento Continuita Cura & Fragilita, Brescia, Italy
[3] Univ Brescia, Brescia, Italy
来源：
CEPHALALGIA | 2023年 / 43卷 / 1supp期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC23-PO-2
引用
收藏
页码：253 / 254
页数：2
相关论文
共 50 条
  • [21] Could Symptom Severity Predict the Response to Anti-Cgrp Monoclonal Antibodies in Migraine?
    Membrilla, J. A.
    Ruiz Castrillo, M. J.
    Sastre Real, M.
    Sanchez Casado, L.
    Marino Trillo, E.
    Corral, C.
    Estebas, C.
    Gonzalez Sarmiento, R.
    Lorenzo, M.
    Diaz de Teran, J.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [22] Patterns of response to anti-CGRP monoclonal antibodies after 6-months of treatment in resistant migraine patients
    Torres-Ferrus, M.
    Alpuente, A.
    Gine-Cipres, E.
    Caronna, E.
    Gallardo Lopez, V.
    Pozo-Rosich, P.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 264 - 265
  • [23] Placebo effects in clinical trials of anti-CGRP monoclonal antibodies for migraine prevention
    Regnier, S.
    Lee, X. Ying
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [24] Late response to anti-CGRP monoclonal antibodies occurs in one-third of migraine patients
    Aurilia, C.
    Egeo, G.
    Fiorentini, G.
    Cevoli, S.
    Messina, R.
    Torelli, P.
    Salerno, A.
    Albanese, M.
    Carnevale, A.
    d'Onofrio, F.
    Finocchi, C.
    Altamura, C.
    Aguggia, M.
    Mercuri, B.
    Bono, F.
    Grazzi, L.
    D'Amico, D.
    Filippi, M.
    Colombo, B.
    Frediani, F.
    Favoni, V
    Di, Fiore P.
    Bertuzzo, D.
    Zucco, M.
    Di Clemente, L.
    Trimboli, M.
    Proietti, S.
    Bonassi, S.
    Vernieri, F.
    Barbanti, P.
    HEADACHE, 2022, 62 : 150 - 151
  • [25] Could symptom severity predict the response to anti-CGRP monoclonal antibodies in migraine?
    Membrilla, J.
    Ruiz Castrillo, M.
    Sastre Real, M.
    Sanchez Casado, L.
    Trillo Marino, E.
    Corral, C.
    Estebas, C.
    Gonzalez Sarmiento, R.
    Lorenzo, M.
    Diaz de Teran, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 413 - 413
  • [26] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
    Hugo Sevivas
    Paula Fresco
    European Journal of Medical Research, 27
  • [27] Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
    Negro, Andrea
    Martelletti, Paolo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (08) : 769 - 776
  • [28] Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: A prospective study of 63 patients
    Castrillo, Ana
    Mendoza, Amelia
    Caballero, Lorena
    Cerdan, Debora
    Rodriguez, Maria Fernanda
    Guerrero, Pilar
    Tabernero, Cesar
    Ferrero, Marta
    Benito, Ines
    Marin, Laura
    Duarte, Jacinto
    MEDICINA CLINICA, 2023, 160 (08): : 341 - 346
  • [29] Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
    Sevivas, Hugo
    Fresco, Paula
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2022, 27 (01)
  • [30] Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
    Amy R. Tso
    Peter J. Goadsby
    Current Treatment Options in Neurology, 2017, 19
12345